Article

Development of a bispecific Antibody–Drug Conjugate targeting CD7 and CD33 to treat Acute Myeloid Leukaemia

2022-07-18

Abstract excerpt

Acute myeloid leukemia (AML) is a heterogeneous malignancy of the bone marrow associated with poor outcomes and limited treatment options available to patients. Recent developments have demonstrated that patient stratification based on disease classification (e.g. somatic mutations) allows for selective treatment regimens and greatly improved outcomes. AML patients can also be stratified based upon the heterogeneo...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: dff9e917-a55d-5621-9b2f-6b841e70b43f
DOI: 10.1101/2022.07.17.500350

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Development of a bispecific Antibody–Drug Conjugate targeting CD7 and CD33 to treat Acute Myeloid LeukaemiaDOI 10.1101/2022.07.17.500350Read

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.Semantic proximity Read

SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AMLSemantic proximity Read

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.Semantic proximity Read

CD33-CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T Cells.Semantic proximity Read

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemiaSemantic proximity Read

Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugateSemantic proximity Read

Rational Combinatorial Targeting by Adapter CAR T Cells (AdCAR-T) Prevents Antigen Escape in Acute Myeloid Leukemia (AML)Semantic proximity Read

In-depth comparative characterization identifies scalable CD123-CAR-NK cells as promising strategy to combat AMLSemantic proximity Read

Targeting CD33 for Acute Myeloid Leukemia TherapySemantic proximity Read

Anti-CD117 immunotherapy to eliminate hematopoietic and leukemia stem cellsSemantic proximity Read

Targeting CD33 for acute myeloid leukemia therapy.Semantic proximity Read

Differential TIM-3 glycosylation enables specific dual targeting CAR-T therapy in acute myeloid leukemiaSemantic proximity Read